ANTEOTECH LTD — Capital/Financing Update 2013

Jun 30, 2013

==> picture [208 x 115] intentionally omitted <==

1 July 2013

Company Announcements Office Australian Stock Exchange Level 6, 20 Bridge Street Sydney NSW 2000

Anteo Receives $1.7 Million grant from Commercialisation Australia

• Grant of $1.7m to assist with funding of a two year project that commenced in April 2013

• Project aims to establish significant market presence for Mix&Go™

• Major In Vitro Diagnostic (IVD), Point of Care (PoC) and Life Science Research (LSR) companies targeted

• Targets intended to demonstrate versatility of Mix&Go™across a range of surfaces and applications

1 July 2013: Anteo Diagnostics Limited (ASX: ADO) (“Anteo”) is very pleased to announce that it has been – successful in its application for a Commercialisation Australia Early Stage Commercialisation Grant. Commercialisation Australia, an initiative of the Australian Government, is a competitive, merit based assistance program offering funding to accelerate the business building process. The grant is worth $1,696,431 over the two-year tenure of the project.

Anteo has developed Mix&Go ™ , a surface chemistry, which is broadly applicable for use in diagnostic tests within the LSR, IVD and PoC markets. To be commercially successful with Mix&Go ™ , Anteo needs to enter into licensing and supply agreements with companies across those markets and on a range of synthetic surfaces relevant to these markets.

Due to the novel, disruptive nature of Mix&Go ™ , significant pre-adoption testing is mandatory by companies before incorporating it into their commercial products. The project has been designed to achieve a range of objectives across the relevant market segments with the ultimate goal of signing licensing and supply agreements with companies in those segments.

Anteo’s Chief Executive Officer Dr Geoff Cumming said: “We are very pleased to have been successful in being awarded a highly sought after Commercialisation Australia Grant in this fiercely competitive environment. We feel that it represents an endorsement of our corporate strategy and recognise that the Government views it as an investment. In return we are expected to provide an ongoing source of employment for extremely talented, highly trained, individuals along with increasing our levels of export revenues. These are obligations we don’t take lightly.”

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

“Given our future expenditure estimates, we believe we now have sufficient working capital to meet our needs through to the end of 2014 in the absence of additional revenues. The activities outlined above, coupled with existing projects, enhance our expectation of revenues before that time.

“Our work in the nanoparticle project continues to deliver very promising results in what we consider to be another highly fertile, commercially attractive field for Anteo to explore. Should further positive results emerge it is likely that we will file new patents and invest in additional resources to commercially exploit our position in markets associated with these exciting findings.”

ENDS

For More Information Contact:

Dr Geoff Cumming, CEO Anteo Diagnostics Limited Tel: +61 7 3219 0085

Sam Sloane Six Degrees Investor Relations Tel: +61 2 9230 0661

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com